ArticleMacromolecular bioscience2025
Investigating How All-Trans Retinoic Acid Polycaprolactone (atRA-PCL) Microparticles Alter the Material Properties of 3D Printed Fibrin Constructs.
Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pure Chitosan Microfluidic Spinning Affords Modular Core-Sheath Fibers and Hand-Crafted Scaffolds with Enhanced Fibroblast Compatibility.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Investigating How All-Trans Retinoic Acid Polycaprolactone (atRA-PCL) Microparticles Alter the Material Properties of 3D Printed Fibrin Constructs.Macromolecular bioscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The 3D printing of human tissue constructs requires carefully designed bioinks to support the growth and function of cells. Here it is shown that an additional parameter is how drug-releasing microparticles affect the material properties of the scaffold. A microfluidic platform is used to create all-trans retinoic acid (atRA) polycaprolactone (PCL) microparticles with a high encapsulation efficiency (85.9 ± 5.0%), and incorporate them into fibrin constructs to investigate their effect on the material properties. An encapsulation that is around 25-35% higher than the current state of the art batch methods is achieved. It is also found that the drug loading concentration affects the microparticle size, which can be controlled using the microfluidic platform. It is shown that the release of atRA is slower in fibrin constructs than in buffer, and that the presence of atRA in the microparticles modulates both the degradation and the rheological properties of the constructs. Finally, it is shown that the fibrin material exhibits a stronger solid-like state in the presence of atRA-PCL microparticles. These findings establish a basis for understanding the interplay between drug-releasing microparticles and scaffold materials, paving the way for bioinks that achieve tailored degradation and mechanical properties, together with sustained drug delivery for tissue engineering applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.